Wearable ID system could pave way to passive mHealth interoperability

transradial, wrist - 63.17 Kb
Researchers at Dartmouth College in Hanover, N.H., have demonstrated the feasibility of a wearable sensor that they designed to passively recognize people. If successful, the prototype they hope to build from their study will curtail mistaken-identity errors in, and malicious hacking of, mobile and wearable medical devices.

Led by Cory Cornelius, a PhD candidate in the school’s department of computer science, the team presented a paper Aug. 7 describing the way their bracelet-like sensor uses bioimpedance—the physiological response to electric current passing through human tissue—to give mHealth sensors the ability to verify the wearer’s identity.

The team studied their approach on 46 adult subjects and found a wearer-recognition accuracy rate of at least 85 percent. Accuracy reached 90 percent when they combined the method with measurements allowing for an error of 1 mm in wrist circumference.

The all-Dartmouth team included four computer scientists, an engineer and an adjunct assistant professor of surgery from Dartmouth’s Geisel School of Medicine.

If an mHealth system knows the identity of its wearer, “the system can properly label and store data collected by the system,” they wrote. “Existing recognition schemes for such mobile applications and pervasive devices are not particularly usable—they require active engagement with the person (e.g., the input of passwords), or they are too easy to fool (e.g., they depend on the presence of a device that is easily stolen or lost).”

The group presented the paper, “Who Wears Me? Bioimpedance as a Passive Biometric,” at a Usenix workshop on health security and privacy.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.